Friday, July 10, 2026
🇺🇸 FDA

pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis

PARItec

Pari Pharma GmbH

PARItec trial registry — 248 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
Status
Public
HQ
Starnberg, DE
Employees
28
Programs
248
Drugs
362
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Trials

PARItec clinical trials

Registry index of 248 ClinicalTrials.gov studies linked to PARItec programs — each row shows trial ID, program name, phase, status, and indication.

PARItec trial registry — 248 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for PARItec.

  1. APHP220916 — Phase 2

    Clinical update

  2. APHP211046 — Phase 3

    Clinical update

  3. A phase 2 trial assessing Ifenprodil as a ReM... for Multiple sclerosis — Phase 2

    Clinical update

  4. Kineret / solution for Familial Mediterranean Fever (F… — Phase 3

    Clinical update

  5. P170916J — Phase 3

    Clinical update

  6. P170913J — Phase 3

    Clinical update

  7. P160925J — Phase 3

    Clinical update

  8. P160909 — Phase 2

    Clinical update

Trial registry

248 studies
  2. 2023-503283-17-00

    APHP220806

    Approved active small_molecule

    Women who delivered by caesarean and have a moderate postpartum iron deficiency anaemia defined by 8.0 g/dL ≤ postoperative Hb level ≤ 10.0 g/dL within 72h after delivery and a ferritinemia ≤ 100 ng/mL OR transferrin saturation ≤ 20% (Measured after postoperative Hb level measurement)

    CTIS ↗
  12. 2023-505278-13-00

    APHP220916

    Phase 2 active small_molecule

    -women with an inflammatory HCA proven at histology and with at least one inflammatory HCA of more than 5 cm. -male with at least one inflammatory HCA proven at histology whatever the size and considered as non resectable by the multidisciplinary tumor board

    CTIS ↗
  28. 2023-507010-27-00

    APHP211003

    Phase 3 active small_molecule

    Primary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cushing Syndrome (Mild autonomous Cortisol secretion)

    CTIS ↗
  35. 2023-508071-36-00

    APHP191099

    Phase 3 active small_molecule

    Patients hospitalised in intensive care, diagnosed with sepsis less than 48 hours ago, uric acid level ≥200µmol/L, adults, negative G6PD deficiency

    CTIS ↗
  40. 2023-508785-16-00

    APHP230813

    Phase 3 active small_molecule

    Very preterm neonate (gestational age at birth < 32 WG) with corrected gestational age <45 WG) with indication for sedation in the context of invasive mechanical ventilation

    CTIS ↗
  45. 2023-509722-22-00

    APHP221166

    Phase 2 active small_molecule

    gram-negative bacillus pneumonia acquired during mechanical ventilation in patients receiving Extracorporeal Membrane veno-arterial oxygenation

    CTIS ↗
  54. 2024-510602-90-00

    APHP230855

    Phase 3 active small_molecule

    Patients presenting with acute myocarditis proven by cardiac magnetic resonance imaging (CMRi) or by histological evidence on endomyocardial biopsy (EMB)

    CTIS ↗
  56. 2024-510941-32-00

    APHP220826

    Phase 3 active small_molecule

    Adult patients discharged alive from ICU with a decreased eGFR, and/or an AKI during ICU stay and/or an elevated NT-proBNP at discharge.

    CTIS ↗
  59. 2024-510981-18-00

    APHP231089

    Phase 3 active small_molecule

    Multiple Myeloma Multiple myeloma (MM) is a B cell malignancy and is one of the most frequent primary neoplasms of the bone marrow

    CTIS ↗
  71. 2024-511862-35-00

    P160954J

    Phase 2 active other

    Adults with non-contrast-enhancing diffuse brainstem gliomas with non-threatening infiltrative clinical and/or radiological progression, Adult brain stem gliomas

    CTIS ↗
  78. 2024-511880-27-00

    APHP200080

    Phase 2 active small_molecule

    Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection, and for the standard of care including concurrent temoradiation followed by adjuvant TMZ with or without Tumor Treating Fields*. (*Tumor Treating Fields is applicable only in participating centers in France)

    CTIS ↗
  82. 2024-511898-30-00

    DEXMEDETOMIDINE , 18F-DPA-714

    Phase 3 active small_molecule

    Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.

    CTIS ↗
  94. 2024-512763-32-00

    APHP230852

    Phase 3 active small_molecule

    Patients diagnosed at the study sites with rifampicinresistant tuberculosis during the recruitment period will be evaluated for study inclusion.

    CTIS ↗
  112. 2024-513645-37-00

    P170912J

    Phase 3 active small_molecule

    Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery)

    CTIS ↗
  123. 2024-513710-35-00

    APHP230836

    Phase 3 active small_molecule

    Patients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in nature, occurs within a 72 hour window, and consists of a decrease in hearing of ≥30 decibels affecting at least 3 consecutive frequencies: 1. A history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. 2. A unilateral sensorineural hearing loss demonstrable on a pure‐tone audiogram at the time of entry into the trial. 3. No other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment. 4. No history of fluctuating sensorineural hearing loss or otologic disease.

    CTIS ↗
  131. 2024-514243-29-01

    PEGASPARGASE

    Phase 3 active small_molecule

    This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic characterization (B- or T- lineage) and the patient risk group, that aims at evaluating the efficacy and the tolerance of different schedules of pegaspargase in patients from 12 months to less than 18 years newly diagnosed with standard/medium-risk ALL

    CTIS ↗
  135. 2024-514347-28-00

    APHP180560

    Phase 3 active small_molecule

    Men and women over 18 years of age with renal failure renal failure stages 3b/4/5, renal transplantation or dialysis and an untreated gout attack

    CTIS ↗
  145. 2024-514606-31-00

    LENVIMA 4 mg hard capsules

    Phase 2 active small_molecule

    Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eligible for PA and comprising at least one of the following criteria: - Single tumour>3 cm≤ 5cm or - multiple tumours (max 3 lesions ≤ 3cm) or - Single tumour between 2 and 3 cm with at least one of the following characteristic: • Serum AFP>100 ng/mL • Infiltrative form • Macro-trabecular subtype (if applicable)

    CTIS ↗
  153. 2024-515018-42-00

    APHP200042

    Phase 2 active small_molecule

    Patients treated with lithium carbonate for a bipolar disorder treated for at least 5 years and with a urine concentration defect.

    CTIS ↗
  156. 2024-515037-15-00

    APHP190205

    Phase 2 active small_molecule

    PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION

    CTIS ↗
  168. 2024-516058-23-00

    APHP210090

    Phase 3 active small_molecule

    Adult patients admitted to the ICU for management of severe influenza infection requiring orotracheal intubation for invasive mechanical ventilation

    CTIS ↗
  178. 2024-516167-86-00

    APHP200072

    Phase 3 active small_molecule

    Patients referred for an isolated or a combined surgical correction of functional moderate to severe tricuspid regurgitation

    CTIS ↗
  190. 2024-516374-29-00

    APHP200002

    Approved active small_molecule

    Patients with excessive supraventricular ectopies or short atrial runs (ESVEA) defined as ≥ 1% premature atrial contractions (PAC) /24 hours or any atrial runs ≥ 20 PACs (but shorter than 30 seconds) on a 24-hour Holter ECG monitoring and CHA2DS2VASC score ≥ 3. Patients with any atrial runs ≥ 20 PACs but shorter than 30 seconds on a 15-21 days Holter ECG monitoring and CHA2DS2VASC score ≥ 3 may also be included in the Short-Run trial.

    CTIS ↗
  205. 2024-516687-28-00

    APHP200026

    Phase 3 active small_molecule

    Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.

    CTIS ↗
  217. 2024-519986-23-00

    CYCLOPHOSPHAMIDE

    Phase 3 active small_molecule

    The study will involve adult women and men from 16 French centers who have hematological malignancies and are candidates for haploidentical HSCT

    CTIS ↗
  239. 2025-521967-11-00

    APHP241595

    Phase 2 active small_molecule

    The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.